Lymphocytes Absent malady

Categories: Rare diseases, Immune diseases

Aliases & Classifications for Lymphocytes Absent

Aliases & Descriptions for Lymphocytes Absent:

Name: Lymphocytes Absent 50


Summaries for Lymphocytes Absent

MalaCards based summary : Lymphocytes Absent is related to paroxysmal nocturnal hemoglobinuria and hemoglobinuria. An important gene associated with Lymphocytes Absent is LBR (Lamin B Receptor). The drugs Mycophenolic acid and Mycophenolate mofetil have been mentioned in the context of this disorder.

Related Diseases for Lymphocytes Absent

Diseases related to Lymphocytes Absent via text searches within MalaCards or GeneCards Suite gene sharing:

id Related Disease Score Top Affiliating Genes
1 paroxysmal nocturnal hemoglobinuria 9.5
2 hemoglobinuria 9.5

Symptoms & Phenotypes for Lymphocytes Absent

Drugs & Therapeutics for Lymphocytes Absent

Drugs for Lymphocytes Absent (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 283)
id Name Status Phase Clinical Trials Cas Number PubChem Id
Mycophenolic acid Approved Phase 4,Phase 1,Phase 2 24280-93-1 446541
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 1,Phase 2 128794-94-5 5281078
Cyclosporine Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1 79217-60-0, 59865-13-3 5284373 6435893
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1 22916-47-8 4189
Praziquantel Approved, Vet_approved Phase 4 55268-74-1 4891
6 HIV Integrase Inhibitors Phase 4
7 Anti-Bacterial Agents Phase 4,Phase 3,Phase 1,Phase 2
8 Immunoglobulin A Phase 4
9 Anti-HIV Agents Phase 4,Phase 1,Phase 2
10 Anti-Infective Agents Phase 4,Phase 3,Phase 1,Phase 2
11 Immunosuppressive Agents Phase 4,Phase 3,Phase 1,Phase 2
12 Integrase Inhibitors Phase 4
13 Antilymphocyte Serum Phase 4,Phase 1,Phase 2
14 Raltegravir Potassium Phase 4
15 Anti-Retroviral Agents Phase 4,Phase 1,Phase 2
16 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 1,Phase 2
17 Antirheumatic Agents Phase 4,Phase 3,Phase 1,Phase 2
18 Calcineurin Inhibitors Phase 4,Phase 1,Phase 2
19 Antiviral Agents Phase 4,Phase 3,Phase 1,Phase 2
20 Thrombin Phase 4
21 Coagulants Phase 4
22 Hemostatics Phase 4
23 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1
24 Anthelmintics Phase 4
25 Antifungal Agents Phase 4,Phase 2,Phase 1
26 Antiparasitic Agents Phase 4,Phase 2
Doxorubicin Approved, Investigational Phase 3,Phase 2 23214-92-8 31703
Vinblastine Approved Phase 3,Phase 2 865-21-4 13342 241903
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
Etoposide Approved Phase 3,Phase 1 33419-42-0 36462
Cyclophosphamide Approved, Investigational Phase 3,Phase 1,Phase 2 50-18-0, 6055-19-2 2907
rituximab Approved Phase 3,Phase 1,Phase 2 174722-31-7 10201696
Bleomycin Approved Phase 3 11056-06-7 5360373
Procarbazine Approved Phase 3 671-16-9 4915
Prednisolone Approved, Vet_approved Phase 3,Phase 1,Phase 2 50-24-8 5755
Dacarbazine Approved, Investigational Phase 3,Phase 2,Phase 1 4342-03-4 5351166
Lenograstim Approved Phase 3,Phase 2,Phase 1 135968-09-1
Methylprednisolone Approved, Vet_approved Phase 3,Phase 1,Phase 2 83-43-2 6741
Prednisone Approved, Vet_approved Phase 3,Phase 1,Phase 2 53-03-2 5865
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 1 50-02-2 5743
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
Cisplatin Approved Phase 3,Phase 2 15663-27-1 84093 441203 2767
Cytarabine Approved, Investigational Phase 3,Phase 2 147-94-4 6253
Methotrexate Approved Phase 3,Phase 2 1959-05-2, 59-05-2 126941
Vinorelbine Approved, Investigational Phase 3,Phase 2 71486-22-1 60780 44424639
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
Iron Approved Phase 3 7439-89-6 23925
Acetaminophen Approved Phase 3 103-90-2 1983
Succinylcholine Approved Phase 3 306-40-1 5314
Goserelin Approved Phase 3,Phase 2 65807-02-5 47725 5311128

Interventional clinical trials:

(show top 50) (show all 211)
id Name Status NCT ID Phase
1 Impact of Raltegravir on the Viral Reservoirs Unknown status NCT01249560 Phase 4
2 A Study of Mycophenolate Mofetil and Cyclosporin, Without Concomitant Corticosteroids, After a First Renal Transplant Completed NCT00200551 Phase 4
3 Mycophenolate Mofetil for IgA Nephropathy Completed NCT00863252 Phase 4
4 Safety and Immunogenicity Study of Recombinant Thrombin (rThrombin) in Pediatric Participants Completed NCT00859547 Phase 4
5 Evaluation of Praziquantel Dosage for Treatment of Schistosomiasis in Brazil Completed NCT00403611 Phase 4
6 Fludeoxyglucose F 18-PET/CT Imaging in Assessing Response to Chemotherapy in Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Hodgkin Lymphoma Unknown status NCT00678327 Phase 3
7 Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin Lymphoma Completed NCT01026220 Phase 3
8 Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer Completed NCT00347412 Phase 3
9 Efficacy and Safety of Influenza Vaccine During Sarcoidosis Completed NCT01687517 Phase 3
10 Phase IIIB Subcutaneous Abatacept Monotherapy Study Completed NCT00547521 Phase 3
11 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3
12 Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer Completed NCT00661999 Phase 3
13 A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE) Completed NCT00719472 Phase 3
14 Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease Completed NCT00025259 Phase 3
15 Relationship Between T LYmphocytes Depletion and Clinical Response to RITUXimab in Rheumatoid Arthritis (LYRITUX) Recruiting NCT02304354 Phase 3
16 TK008: Efficacy Study on the Strategy of HSV-Tk Engineering Donor Lymphocytes to Treat Patients With High Risk Acute Leukemia Recruiting NCT00914628 Phase 3
17 S1400I Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Recruiting NCT02785952 Phase 3
18 Nivolumab and Ipilimumab With or Without Sargramostim in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery Recruiting NCT02339571 Phase 2, Phase 3
19 High-Dose Recombinant Interferon Alfa-2B, Ipilimumab, or Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery Recruiting NCT02506153 Phase 3
20 Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma Recruiting NCT02224781 Phase 3
21 A Study Comparing BGB-3111 and Ibrutinib in Subjects With Waldenström's Macroglobulinemia (WM) Recruiting NCT03053440 Phase 3
22 S1400 Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer Recruiting NCT02154490 Phase 2, Phase 3
23 Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer Active, not recruiting NCT02003209 Phase 3
24 Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery Active, not recruiting NCT01274338 Phase 3
25 Evaluating Safety and Efficacy of TOL101 Induction Versus Anti-Thymocyte Globulin to Prevent Kidney Transplant Rejection Unknown status NCT01154387 Phase 1, Phase 2
26 Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas Unknown status NCT01805037 Phase 1, Phase 2
27 Infusion of Donor Lymphocytes Transduced With the Suicide Gene HSV TK in Patients With Haematological Malignancies Completed NCT00423124 Phase 1, Phase 2
28 Safety Study of 5-Azacitidine and Standard Donor Lymphocyte Infusion (DLI) to Treat Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Relapsing After Allogeneic Stem Cell Transplantation Completed NCT00795548 Phase 2
29 Allogeneic Cytokine-induced Killer Immunotherapy for Relapse After Allogeneic Marrow Transplant for Haematological Malignancies Completed NCT00460694 Phase 1, Phase 2
30 Transplantation of Ex-vivo Expanded Cord Blood Stems Cells Completed NCT01034449 Phase 2
31 Laboratory-Treated T Cells and Ipilimumab in Treating Patients With Metastatic Melanoma Completed NCT00871481 Phase 1, Phase 2
32 Vaccine Therapy in Treating Patients With Recurrent Prostate Cancer Completed NCT00109811 Phase 2
33 Ipilimumab Combined With a Stereotactic Radiosurgery in Melanoma Patients With Brain Metastases Completed NCT02662725 Phase 2
34 Safety, False-Positive Reactions and Sensitizing Properties of Leishmania Tropica Skin Test Antigen Completed NCT00633009 Phase 2
35 Laboratory-Treated T Cells and Aldesleukin After Cyclophosphamide in Treating Patients With Stage IV Melanoma Completed NCT00553306 Phase 1, Phase 2
36 Augmentation of Dendritic Cell-Based Vaccines in Melanoma Patients by Depletion of Regulatory T Cells in Stage IV Melanoma Patients Completed NCT00847106 Phase 1, Phase 2
37 Safety and Efficacy of Varying Methods of ALV003 Administration for the Treatment of Celiac Disease Completed NCT01255696 Phase 2
38 Safety and Efficacy of ALV003 for the Treatment of Celiac Disease Completed NCT00959114 Phase 2
39 153Sm-EDTMP With or Without a PSA/TRICOM Vaccine To Treat Men With Androgen-Insensitive Prostate Cancer Completed NCT00450619 Phase 2
40 Bortezomib in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma Completed NCT00082966 Phase 2
41 Immuno-modulation in Amyotrophic Lateral Sclerosis- a Phase II Study of Safety and Activity of Low Dose Interleukin-2 Completed NCT02059759 Phase 2
42 Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy Completed NCT00466960 Phase 2
43 Anti-thymocyte Globulin and Cyclosporine as First-Line Therapy in Treating Patients With Severe Aplastic Anemia Completed NCT01231841 Phase 2
44 Interleukin-12 in Treating Patients With Previously Treated Non-Hodgkin's Lymphoma or Hodgkin's Disease Completed NCT00003210 Phase 2
45 Bortezomib, Ifosfamide, and Vinorelbine Tartrate in Treating Young Patients With Hodgkin's Lymphoma That is Recurrent or Did Not Respond to Previous Therapy Completed NCT00381940 Phase 2
46 Interleukin-12 in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer Completed NCT00016289 Phase 2
47 Vorinostat in Treating Patients With Relapsed or Refractory Advanced Hodgkin's Lymphoma Completed NCT00132028 Phase 2
48 Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma Completed NCT00026143 Phase 2
49 Combination Chemotherapy in Treating Children With Refractory or Relapsed Hodgkin's Lymphoma Completed NCT00006760 Phase 2
50 Gemcitabine and Vinorelbine in Treating Young Patients With Recurrent or Refractory Hodgkin's Lymphoma Completed NCT00070304 Phase 2

Search NIH Clinical Center for Lymphocytes Absent

Genetic Tests for Lymphocytes Absent

Anatomical Context for Lymphocytes Absent

Publications for Lymphocytes Absent

Articles related to Lymphocytes Absent:

id Title Authors Year
Regulation of glycoinositol phospholipid anchor assembly in human lymphocytes. Absent mannolipid synthesis in affected T and natural killer cell lines from paroxysmal nocturnal hemoglobinuria patients. ( 8454600 )

Variations for Lymphocytes Absent

Expression for Lymphocytes Absent

Search GEO for disease gene expression data for Lymphocytes Absent.

Pathways for Lymphocytes Absent

GO Terms for Lymphocytes Absent

Sources for Lymphocytes Absent

9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
32 HPO
33 ICD10
34 ICD10 via Orphanet
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
52 Novoseek
55 OMIM via Orphanet
59 PubMed
65 SNOMED-CT via Orphanet
68 Tocris
70 UMLS via Orphanet
Loading form....